Cardiovascular health and cognition in older adults: Variations across recruitment models and European countries in the MOPEAD project.

BackgroundThe Models of Patient Engagement for Alzheimer's Disease (MOPEAD) project aimed to identify the most effective and cost-efficient recruitment model for detecting prodromal and mild Alzheimer's disease (AD) across five European countries.ObjectiveTo examine differences in cardiovascular risk factors and cognitive performance among countries and recruitment models using MOPEAD data.MethodsIndividuals aged 65-85 with a high risk for prodromal or mild AD were included.

Traction force and mechanosensitivity mediate species-specific implantation patterns in human and mouse embryos.

The invasion of human embryos in the uterus overcoming the maternal tissue barrier is a crucial step in embryo implantation and subsequent development. Although tissue invasion is fundamentally a mechanical process, most studies have focused on the biochemical and genetic aspects of implantation. Here, we fill the gap by using a deformable ex vivo platform to visualize traction during human embryo implantation.

Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma Classification.

Neurodegenerative diseases (including Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, and Dementia with Lewy bodies) pose diagnostic challenges due to overlapping pathology and clinical heterogeneity. We leveraged proteomic data from more than 21,000 cerebrospinal fluid and plasma samples to develop and validate explainable, boosting-based multi-disease AI classifiers. The models achieved weighted AUCs in the testing datasets of 0.

Cerebrospinal fluid biomarkers of Alzheimer's disease in Lewy body diseases: The performance of fully automated immunoassays.

BackgroundThe potential role of Alzheimer's disease (AD) pathology in contributing to cognitive impairment in α-synucleinopathies warrants in vivo detection of the pathological burden in patients with α-synucleinopathies.ObjectiveUsing a fully automated platform, we measured the levels of cerebrospinal fluid (CSF) AD biomarkers, namely Aβ, P-tau181 and T-tau, as well as their derived ratios, P-tau181/Aβ ratio and T-tau/Aβ ratio, in a cohort of Parkinson's disease (PD), dementia with Lewy bodies (DLB), preclinical and prodromal AD (pAD) patients, as well as cognitively normal controls. We binarized the CSF biomarkers and determined the proportion of individuals with abnormal biomarker levels within each diagnostic group.